A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.

More information: Melissa-Rosina Pasqua et al, Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial, Nature Medicine ...

The 26-week PIONEER 5 trial is one of 10 clinical trials for oral semaglutide that are due to complete this year. Novo's oral semaglutide on target in phase 3 trial | pharmaphorum Skip to main content ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

A new study showed that semaglutide may help with alcohol use ... Over the nine-week trial, not only were alcohol cravings reduced, but when those on the medication did drink alcohol, they drank ...

Half received semaglutide, a type of GLP-1 receptor agonist, while the other half received no treatment. Over the nine-week trial, participants taking semaglutide started at a dose of 0.25 mg per ...

This trial involved participants who had obesity or overweight along with at least one weight-related health issue (excluding type 2 diabetes), who were given a 2.4 mg dose of semaglutide.

Semaglutide may work quickly. In a 2021 clinical trial, some participants lost more than 2% of their body weight within 4 weeks. The weight loss pattern continued, and participants lost an average ...

The human laboratory trial (NCT05520775), carried out by the University of North Carolina at Chapel Hill, US, saw nearly 40% of participants dosed with semaglutide report a reduction in their ...